Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: A feasibility study

• DOI: 10.1016/j.lungcan.2022.06.013
• Publication Date: 2022-06-22T15:22:12Z
• Authors: B.M.M. Wever; S. Bach; M. Tibbesma; T.J. ter Braak; D. Wajon; C. Dickhoff; B.I. Lissenberg-W...; A. Hulbert; G. Kazemier; I. Bahce; R.D.M. Steenbergen
• Keywords: Lung Neoplasms; DNA Methylation; Polymerase Chain Reaction; 6. Clean water; Circulating Tumor DNA; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Biomarkers, Tumor; Feasibility Studies; Humans; Prospective Studies

Lung cancer has the highest cancer-related mortality worldwide and earlier detection could improve outcomes. Urine circulating tumor DNA (ctDNA) represents a true non-invasive means for ambulant sample collection. In this prospective study, potential of urine perioperative non-metastatic non-small cell lung (NSCLC) using ctDNA methylation analysis is evaluated.Preoperative samples 46 surgical NSCLC patients 50 sex age-matched controls were analyzed NSCLC-associated markers CDO1, SOX17, TAC1, quantitative methylation-specific PCR (qMSP). The accuracy was determined by univariable multivariable logistic regression analysis, followed leave-one-out cross-validation. Fourteen additional collected postoperatively to evaluate whether levels alter after surgery with curative intent.Methylation CDO1 SOX17 significantly elevated in compared (P =.016 P <.001, respectively). This marker combination yielded an area under receiver operating curve (AUC) value 0.71 upon cross-validation urine. Stage I tended have higher as stage III patients. Similar found across different histological subtypes NSCLC. some preoperative levels, reduced post-operative samples.Urine showed increased sex- controls. demonstrates that may provide interesting detect Further studies are needed validate clinical usefulness approach assess monitoring.